Synageva Biopharma Corp (NASDAQ:GEVA)
During the Trading Day
| 41.38 |  -0.18 / -0.43% |
Data as of 4:00pm ET | Day’s Change |
During After-Hours Switch to standard view »
| 41.38 |  0.00 / 0.00% |
Volume: 4.4K |
Latest GEVA News | Press Releases
No recent news for Synageva Biopharma Corp.
Today’s Trading
| Previous close | 41.56 |
| Today’s open | 41.43 |
| Day’s range | 41.24 - 42.42 |
| Volume | 66,325 |
| Average volume (3 months) | 93,518 |
| Market cap | $1.1B |
| Dividend yield | -- |
Data as of 4:00pm ET, 06/19/2013
Growth & Valuation
| Earnings growth (last year) | +77.86% |
| Earnings growth (this year) | -65.07% |
| Earnings growth (next 5 years) | +36.00% |
| Revenue growth (last year) | +612.51% |
| P/E ratio | NM |
| Price/Sales | 69.89 |
| Price/Book | 4.42 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| IMGNImmunogen Inc | -0.42 | -2.56% |
| ITMNInterMune Inc | +0.14 | +1.42% |
| MNTAMomenta Pharmaceutic... | -0.29 | -2.01% |
| SZYMSolazyme Inc | +0.60 | +4.98% |
Data as of 4:00pm ET, 06/19/2013
Financials
| Next reporting date | August 1, 2013 |
| EPS forecast (this quarter) | -$0.78 |
| Annual revenue (last year) | $15.0M |
| Annual profit (last year) | -$42.9M |
| Net profit margin | -287.21% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Sanj K. Patel |
Chief Financial Officer & Senior Vice President Carsten Boess |
Corporate headquarters Lexington, Massachusetts |
Forecasts
